PTC Therapeutics (NASDAQ:PTCT) Director Sells $83,600.05 in Stock

Key Points

• PTC Therapeutics Director Allan Steven Jacobson sold 1,667 shares for a total of $83,600.05 at an average price of $50.15, reducing his stake by 8.72% to 17,451 shares.
• The company's stock price recently rose to $52.43, with a notable market capitalization of $4.17 billion and an annual trading range between $30.41 and $58.38.
• PTC Therapeutics reported an EPS of ($0.83), surpassing estimates, but the quarterly revenue saw a 4.2% decline compared to the previous year.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Allan Steven Jacobson sold 1,667 shares of the stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $50.15, for a total value of $83,600.05. Following the completion of the transaction, the director owned 17,451 shares in the company, valued at approximately $875,167.65. The trade was a 8.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Allan Steven Jacobson also recently made the following trade(s):

• On Thursday, August 28th, Allan Steven Jacobson sold 1,667 shares of PTC Therapeutics stock. The stock was sold at an average price of $50.15, for a total value of $83,600.05.

PTC Therapeutics Stock Performance

Shares of PTC Therapeutics stock traded up $3.10 on Tuesday, hitting $52.43. The company had a trading volume of 1,780,502 shares, compared to its average volume of 1,083,384. The stock has a market capitalization of $4.17 billion, a price-to-earnings ratio of 7.52 and a beta of 0.53. PTC Therapeutics, Inc. has a 1 year low of $30.41 and a 1 year high of $58.38. The stock has a 50 day moving average of $48.73 and a 200-day moving average of $49.02.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.24. The firm had revenue of $178.88 million during the quarter, compared to the consensus estimate of $173.01 million. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The company's quarterly revenue was down 4.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.29) earnings per share. PTC Therapeutics has set its FY 2025 guidance at EPS. Equities analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Hedge Funds Weigh In On PTC Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Toronto Dominion Bank purchased a new position in shares of PTC Therapeutics in the fourth quarter valued at $148,363,000. Driehaus Capital Management LLC purchased a new position in PTC Therapeutics during the 4th quarter valued at about $46,993,000. Nuveen LLC bought a new stake in shares of PTC Therapeutics during the first quarter valued at about $51,427,000. Point72 Asset Management L.P. lifted its holdings in shares of PTC Therapeutics by 150.6% in the fourth quarter. Point72 Asset Management L.P. now owns 1,443,362 shares of the biopharmaceutical company's stock worth $65,153,000 after buying an additional 867,502 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of PTC Therapeutics by 13.2% in the first quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock worth $276,161,000 after buying an additional 632,049 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently commented on PTCT shares. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $63.00 price target (up from $60.00) on shares of PTC Therapeutics in a research report on Friday, August 8th. Truist Financial increased their price target on PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Cantor Fitzgerald increased their price target on PTC Therapeutics from $112.00 to $120.00 and gave the company an "overweight" rating in a research report on Tuesday, July 29th. Barclays increased their price target on PTC Therapeutics from $42.00 to $46.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 29th. Finally, Citigroup increased their price target on PTC Therapeutics from $40.00 to $50.00 and gave the company a "neutral" rating in a research report on Monday, July 28th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $69.15.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.